OKYO Pharma LtdNASDAQ:OKYO
- LAST PRICE1.9000
- TODAY'S CHANGE (%)0.0200 (1.0638%)
- Bid / Lots1.7100/ 155
- Ask / Lots2.0000/ 5
- Open / Previous Close1.8703 / 1.8800
- Day Range
- 52 Week Range
- Volume30,262
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OKYO |
|---|---|---|
| 10:06 ET | 100 | 1.8703 |
| 10:24 ET | 5400 | 1.91 |
| 10:48 ET | 165 | 1.87 |
| 10:53 ET | 200 | 1.87 |
| 11:22 ET | 100 | 1.92 |
| 11:44 ET | 100 | 1.8713 |
| 11:51 ET | 500 | 1.87 |
| 12:12 ET | 100 | 1.88 |
| 12:43 ET | 100 | 1.885 |
| 02:33 ET | 1100 | 1.9 |
| 02:36 ET | 15070 | 1.92 |
| 02:38 ET | 100 | 1.92 |
| 02:40 ET | 400 | 1.94 |
| 02:51 ET | 2199 | 1.93 |
| 03:07 ET | 202 | 1.92 |
| 03:25 ET | 100 | 1.94 |
| 03:34 ET | 100 | 1.94 |
| 03:41 ET | 275 | 1.94 |
| 03:56 ET | 596 | 1.9 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
OKYO Pharma Ltd | 53.1M | -0.1x | --- |
Kinnate Biopharma Inc | 65.0M | -0.5x | --- |
Mira Pharmaceuticals Inc | 64.3M | 0.0x | --- |
Tiziana Life Sciences Ltd | 67.5M | -4.5x | --- |
Collplant Biotechnologies Ltd | 67.4M | -8.9x | --- |
Xilio Therapeutics Inc | 61.1M | -0.7x | --- |
Company Information
OKYO Pharma Limited is a United Kingdom-based preclinical biopharmaceutical company. The Company is focused on developing an approach to dry eye care and ocular pain that is developing a lipidated chemerin-peptide drug candidate, OK-101, designed to target an ocular receptor controlling inflammation and ocular pain. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The Company operates through the research and development of biotechnological and pharmaceutical products segment. The Company’s technologies include Chemerin Receptor, OK-101 Drug Candidate and Preclinical Data. Its membrane anchored peptide (MAP) technology enabled the development of OK-101. Its drug candidate, OK-101, consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain. The Company’s wholly owned subsidiary is OKYO Pharma US Inc.
Contact Information
- Headquarters
- 55 Park LaneLONDON, United Kingdom W1K 1NA
- Phone
- 207-495-2379
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $53.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 28.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-27.14 |
Book Value | $8.39 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
